Sahajanand Medical Technologies Ltd IPO
- Price band
- ₹327 to ₹344
- Issue size
- ₹475 Cr
- Issue price
- ₹344
- Lot size
- 43 shares
- Listing return
- +7.89%
Listed ₹371.15
Opens
15 Oct 2026
Closes
19 Oct 2026
Allotment
21 Oct 2026
Listing
23 Oct 2026
Subscription
About the company
Sahajanand Medical Technologies Limited makes and sells devices for vascular and structural heart procedures. Started in 2001, its range covers vascular products such as coronary stents and balloon catheters, structural heart items like TAVI devices and occluders, plus renal stents, peripheral drug-coated balloons, and traded medical goods.
Sales happen through direct, hybrid, and distributor channels. In FY26 the company earned revenue from 77 countries, India included, with operations in Europe and other overseas markets. It runs three plants (two in India, one in Thailand) and two R&D centres (India and Thailand) that work on device development and product upgrades.
Use of proceeds
This is an offer-for-sale (OFS), so the company itself gets no money from the issue. Net proceeds go to the promoter selling shareholders in proportion to the shares each offers. The main aim is to list the equity shares on the stock exchanges, which should raise visibility and brand recognition, give existing shareholders liquidity, and create a public market for the shares in India.
Key performance indicators (KPIs)
for the three month period ended June 30, 2026
- ROE2.07%
- ROCE3.16%
- EBITDA Margin13.81%
- PAT Margin4.29%
- Return on Net Worth (RoNW)2.31%
Debt/Equity Ratio
0.33
EPS (Pre IPO)
6.8
Net Asset Value (NAV) per Equity Share
64.3
View table
| KPI | Value (for the three month period ended June 30, 2026) |
|---|---|
| ROE (%) | 2.07 |
| ROCE (%) | 3.16 |
| EBITDA Margin (%) | 13.81 |
| Debt/Equity Ratio | 0.33 |
| PAT Margin (%) | 4.29 |
| EPS (Pre IPO) (₹) | 6.8 |
| Return on Net Worth (RoNW) (%) | 2.31 |
| Net Asset Value (NAV) per Equity Share (₹) | 64.3 |
Financials
₹ croreRevenue
1,210.5
Total Assets
1,276.43
Profit
69.08
View table
| Line | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 901.6 | 1,024.88 | 1,210.5 |
| Total Assets | 970.58 | 1,094.9 | 1,276.43 |
| Profit | -7.35 | 25.15 | 69.08 |
Book running lead managers & registrar
| Book running lead managers | Motilal Oswal Investment Advisors Limited, Avendus Capital Private Limited, HSBC Securities, Capital Markets (India) Private Limited, Nuvama Wealth Management Limited |
|---|---|
| Registrar to the issue | MUFG Intime India Private Limited |
Sahajanand Medical Technologies IPO contact details
| Company name | Sahajanand Medical Technologies Limited |
|---|---|
| Registered office | Sahajanand Estate, Wakharia Wadi, NR. Dabholi Char Rasta, Nani Ved, Ved Road, Surat, Gujarat – 395 004, India |
| Phone | 022 49564000 |
| investors.grievance@smt.in | |
| Website | www.smtpl.com |
Sahajanand Medical Technologies IPO registrar contact details
| Company name | MUFG Intime India Private Limited |
|---|---|
| Phone | +91 810 811 4949 |
| sahajanandmedical.ipo@in.mpms.mufg.com | |
| Website | in.mpms.mufg.com/ |
Thesis
- 1
As per the F&S Report, the company accounted for almost 25% of India's drug-eluting stent (DES) market by sales volume in FY26, and ranked among the top five by DES volume in Germany, Spain, Poland, and Brazil as of March 31, 2026.
- 2
Products reached 77 countries in FY26, and overseas revenue climbed from Rs 587.84 crore in FY24 to Rs 704.23 crore in FY25 and Rs 894.20 crore in FY26, a CAGR of 23.34%.
- 3
Two R&D centres, in Surat and Nonthaburi, back the business; as of the RHP date the company held 119 granted patents worldwide, 78 pending applications, and five design registrations in India, with R&D spending at 9.04%, 9.07%, and 8.61% of revenue in FY24, FY25, and FY26.
- 4
Clinical backing is broad: as of June 30, 2026, 75 studies supported its products (66 finished, nine ongoing), and research has appeared in journals including The Lancet and The New England Journal of Medicine.
- 5
Three plants in Surat, Hyderabad, and Thailand all carry ISO 13485:2016 quality certification, along with approvals such as CDSCO, CE, ANVISA, TGA Australia, and Korean GMP depending on the site.
- 6
Manufacturing is integrated in-house, covering balloon catheters, laser cutting, electropolishing, drug and polymer coating, and valve production; about 33% of available space at the Hyderabad plant is in use, leaving room to expand.
- 7
Acquisitions of Vascular Concepts and Vascular Innovations opened the structural heart segment, while Imex in Spain and Zarek in Brazil strengthened distribution, with revenue from Imex and Zarek growing at CAGRs of 52.10% and 23.91% since acquisition in FY20.
Application details
Regular
₹327 - ₹344 · Upto ₹2 Lakhs
43sharesEmployee
₹327 - ₹344 · Upto ₹5 Lakhs
43sharesHigh Networth Individual
₹327 - ₹344 · ₹2 - ₹5 Lakhs
43sharesMin 602
Figures come from the company filing. This is not a recommendation.